First PREMIER Bank’s Ionis Pharmaceuticals IONS Stock Holding History

First PREMIER Bank’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-250	Closed	-$16K	–	320
2019 Q2	$16K	Hold	250	–	–	0.01%	218
2019 Q1	$20K	Hold	250	–	–	0.01%	203
2018 Q4	$14K	Hold	250	–	–	0.01%	220
2018 Q3	$13K	Hold	250	–	–	0.01%	217
2018 Q2	$10K	Hold	250	–	–	0.01%	207
2018 Q1	$11K	Buy	+250	New	+$12.7K	0.01%	202

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

First PREMIER Bank's IONS Position: Q3 2019 in Review

First PREMIER Bank sold out of Ionis Pharmaceuticals (IONS) in Q3 2019, closing a stake of 250 shares — an estimated $16K sold.

First PREMIER Bank first reported a position in IONS in Q1 2018 and held it in 6 quarters. The position peaked at $20K in Q1 2019. 369 funds tracked by Wall St. Rank hold IONS as of Q3 2019.

First PREMIER Bank reported no remaining Ionis Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
First PREMIER Bank sold 250 Ionis Pharmaceuticals shares in Q3 2019, an estimated $16K.
First PREMIER Bank first reported a position in Ionis Pharmaceuticals in Q1 2018 and held it in 6 quarters.
First PREMIER Bank's Ionis Pharmaceuticals position peaked at $20K in Q1 2019.
369 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2019.

Based on First PREMIER Bank's 13F filing for Q3 2019, filed 10 Oct 2019.